Working… Menu

AZMATICS: AZithroMycin/Asthma Trial In Community Settings

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00266851
Recruitment Status : Completed
First Posted : December 19, 2005
Results First Posted : September 6, 2019
Last Update Posted : September 6, 2019
American Academy of Family Physicians
Dean Foundation
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:

The purpose of this study is to assess the effectiveness of the azalide macrolide azithromycin in adults with persistent asthma.

Research Question: Will a 12-week treatment with the antibiotic, azithromycin, result in a statistically significant and clinically meaningful improvement in overall asthma symptoms and other patient-oriented asthma outcomes one year after initiation of treatment of adult primary care patients with asthma?

Experimental Design: The investigators propose a one-year randomized, placebo-controlled, blinded (investigator, patient, data collector, data analyst) trial of 12 weekly doses of azithromycin/placebo as adjunctive therapy (in addition to usual care) along with a parallel observational cohort who will participate 'open label' in 100 adult asthma patients recruited from practice-based research networks (e.g., Wisconsin Research and Education Network (WREN) and others). This "practical clinical trial" will (1) enroll a representative sample of asthma patients encountered in the practices of primary care physicians, (2) employ standard clinical trial methodology to ensure internally valid results and (3) measure outcomes important to patients, so that the results will be valid and applicable to the kinds of asthma patients encountered by family physicians and other primary care providers.

Active study sites -

  • Wisconsin: Augusta, Cross Plains, La Crosse, Marshfield, Milwaukee, Madison,
  • Mauston, Rice Lake, Tomah, Wausau
  • Colorado: Monument
  • Illinois: Peoria
  • Nevada: Reno
  • North Carolina: Granite Falls
  • North Dakota: Minot
  • Ohio: Cleveland, Berea
  • Oklahoma: Ardmore, Claremore, Edmond, Lawton, Oklahoma City, Stroud, Tulsa, Weatherford
  • Rhode Island: East Providence

Condition or disease Intervention/treatment Phase
Asthma Drug: Azithromycin Drug: Placebo Phase 3

Detailed Description:


Approximately 100 eligible adult patients with physician-diagnosed asthma will either be randomized to 12-week treatment with azithromycin or an identical placebo, or join an observational open-label azithromycin cohort. Azithromycin is a widely marketed azalide antibiotic with an excellent safety profile. Azithromycin or placebo will be adjunctive therapy for usual asthma care. The following patient-reported data will be collected via Zoomerang™ (a commercially-available data collection tool) periodically until one year after randomization: (1) study medication adherence and side effects weekly until 12 weeks, (2) asthma control and exacerbations every 6 weeks until 12 months, and (3) asthma quality of life and asthma controller medication changes every 3 months until 12 months. The primary hypothesis is that azithromycin will significantly improve asthma control (decrease symptoms and medication use) by 3 months (end treatment) and the improvement will continue to 12 months (end study). The primary outcome variable is overall asthma symptoms. Secondary outcomes are asthma medication use, quality of life and exacerbations. We will examine the predictive value of baseline patient characteristics including age, sex, smoking, co-morbid respiratory diagnoses and degree of airflow limitation. We will also examine for any imbalances between study groups in controller medication use, other antibiotic prescriptions and acute respiratory illnesses during the one-year study period.

We will enroll subjects from the practices of Wisconsin Research and Education Network (WREN) members, UW Department of Family Medicine physicians, Dean Medical Center primary care physicians, and from other practice-based research networks (PBRNs), medical group practices and individual primary care practices throughout North America.

Patients with physician-diagnosed asthma aged 18 and older will be identified at point-of-service (office, urgent care, emergency room or hospital), by administrative data base review, or by physician recall. Most subjects will be the patients of study physicians. Other physicians in the group practice may refer subjects. Subjects also may be self-referred after responding to posters placed in the clinics. Some sites may elect to identify cases by medical record or database review, in which case only the personal physician may initiate patient contacts.

Treatment is azithromycin tablets, 600 milligrams orally once daily for 3 days, then 600 milligrams once weekly for an additional 11 weeks (total dose 8400 milligrams) or identical placebo, in addition to usual care for asthma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2 arms are randomized, placebo-controlled, double-blinded, 1 arm was added as an open-label observational cohort
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: AZMATICS: Azithromycin Asthma Trial In Community Settings
Study Start Date : January 2006
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: Azithromycin
Active adjunctive treatment
Drug: Azithromycin
600 mg x 3 days, then 600 mg weekly x 11 weeks
Other Name: Zithromax

Placebo Comparator: Placebo
Adjunctive placebo
Drug: Placebo
Matching placebo

Observational Cohort
Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
Drug: Azithromycin
600 mg x 3 days, then 600 mg weekly x 11 weeks
Other Name: Zithromax

Primary Outcome Measures :
  1. Change in Overall Asthma Symptoms From Baseline [ Time Frame: Within the past 24 hours; measured every 1.5 months for one year ]
    5-point scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=worst ever, the lower scores indicate improvement in asthma symptoms

Secondary Outcome Measures :
  1. Change in Asthma Control Over Baseline [ Time Frame: Within the past week; every 3 months ]
    Mini-Juniper Asthma Control Questionnaire without pulmonary function. This is a 6-item survey scored on a 7 point scale where 0 is none, or no symptoms and 6 is severe or symptoms all of the time. Answers are averaged for a final score of 0-6. Data are reported as a change from baseline.

  2. Change is Asthma-specific Quality-of-Life (AQL) [ Time Frame: Within the past 2 weeks; every three months ]
    Juniper Asthma Quality of Life Questionnaire is a 32-item survey, recall of the past 2 weeks, scored on a 7 point Likert scale where 1 is severely impaired, and 7 is not impaired at all. Scores are averaged for a final range of 1-7. Change from Baseline is reported here.

  3. Asthma Exacerbations [ Time Frame: up to 12 months ]
    A steroid burst, an unscheduled or emergency visit and/or a hospitalization for asthma, reported at Weeks 0, 6, 12, 18, 24, 30, 36, 42, 48, and any time during follow up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 and older (and at least 50 kg/110 pounds)

    • The lower weight limit was chosen to avoid exposure to greater than 12 mg/kg/day of azithromycin (a currently recommended dose for children)
    • We specify no upper age limit because asthma occurs throughout the age range and because asthma in the elderly is particularly severe and warrants inclusion.
  • Physician-diagnosed asthma
  • At the time of randomization, eligible subjects must either:

    • be having a documented asthma exacerbation OR
    • be reporting at least mild persistent asthma symptoms, as defined by GINA (Global Initiative for Asthma)
  • Subjects must also have asthma symptoms for at least six months prior to randomization
  • Documentation of objective evidence of reversible airway obstruction, either spontaneously or after treatment, is required prior to randomization. This requirement can be met by documentary evidence, within 2 years of randomization, of either:

    • a 12% or greater (and ≥200 mL) change in FEV1 OR
    • a 25% or greater (and >60 L/min) change in PEFR either spontaneously or as a result of treatment

Exclusion Criteria:

  • Not English literate or without email and internet access
  • Macrolide allergy
  • Pregnancy or lactation
  • Females of childbearing potential must agree to use an acceptable form of contraception during the treatment period
  • Chronic use of macrolides, tetracyclines or quinolones Chronic use is defined as 4 or more weeks of continuous use within 6 months of randomization
  • Asthma symptoms for less than 6 months prior to randomization Asthma symptoms must be present for at least 6 months to exclude patients without true chronic asthma
  • Unstable asthma requiring immediate emergency care All patients with asthma exacerbations will receive usual urgent or emergency care for asthma and must be improving or stable in the judgment of the treating physician prior to being enrolled
  • Specified co-morbidities likely to interfere with study assessments or follow up. Excluded comorbidities include:

    • cystic fibrosis
    • obstructive sleep apnea requiring CPAP
    • cardiomyopathy
    • congestive heart failure
    • terminal cancer
    • alcohol or other drug abuse
    • or any other serious medical condition that, in the opinion of the study physician, would seriously interfere with or preclude assessment of study outcomes or completion of study assessments
  • Specified medical conditions for which macrolide administration may possibly be hazardous
  • Patients with acute or chronic hepatitis, cirrhosis or other liver disease, chronic kidney disease, or history of prolonged cardiac repolarization and QT interval or torsades de pointes, are excluded
  • Specified medications for which close monitoring has been recommended in the setting of macrolide administration Patients taking digoxin, theophylline, warfarin, ergotamine or dihydroergotamine, triazolam, carbamazepine, cyclosporine, hexobarbital or phenytoin are excluded.

    • If any of these medications are started after randomization and before completion of the 12-week treatment phase, study medication will be discontinued and the patient may remain in the study.

The intent of this protocol is to enroll a broadly generalizable sample of adult patients with physician-diagnosed asthma, either stable persistent or in exacerbation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00266851

Layout table for location information
United States, Illinois
Peoria, Illinois, United States, 61602
United States, Kansas
AAFP National Research Network
Kansas City, Kansas, United States, 66211
United States, Ohio
RAP - Cleveland Clinic
Cleveland, Ohio, United States, 44130
United States, Oklahoma
University of Oklahoma Health Sciences Center (OUHSC) and Oklahoma Physicians Resource/Research Network (OKPRN)
Oklahoma City, Oklahoma, United States, 73104
United States, Wisconsin
Wisconsin Research and Education Network (WREN)
Madison, Wisconsin, United States, 53713
Sponsors and Collaborators
University of Wisconsin, Madison
American Academy of Family Physicians
Dean Foundation
Layout table for investigator information
Principal Investigator: David L Hahn, MD, MS Wisconsin Research and Education Network (WREN)
Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT00266851    
Other Study ID Numbers: H-2005-0258
First Posted: December 19, 2005    Key Record Dates
Results First Posted: September 6, 2019
Last Update Posted: September 6, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Wisconsin, Madison:
Randomized clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Bacterial Agents
Anti-Infective Agents